2:57 PM · 9 February 2021

Tilray soared in pre-market on medical cannabis agreement

Tilray (TLRY.US), a pharmaceutical and cannabis company, gained roughly 20% in pre-market trading as the firm announced it has entered into an agreement with Grow Pharma - the leader in supplying unlicensed cannabis medicines in the UK. Under the agreement, Grow Pharma will distribute Tilray’s medical cannabis products across the United Kingdom. Tilray’s stock price skyrocketed in recent weeks, which might be associated with hopes that Joe Biden could potentially introduce federal marijuana legalisation. 

Tilray (TLRY.US) gained in recent weeks as Biden is expected to support medical cannabis legalisation. Stock price climbed above key area at $22.45 and is expected to open almost 20% higher today. Source: xStation5

20 October 2026, 6:41 PM

Daily Summary: Buyers Refuse to Give In

20 October 2026, 4:53 PM

CoreWeave: Record Demand Collides with Crushing Costs

20 October 2026, 2:38 PM

US OPEN: The wave of AI concerns is building again, oil returns near highs

20 October 2026, 1:37 PM

SpaceX must show that Starlink can fund the Group’s growing ambitions

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits